Design Therapeutics (DSGN) Interest Income - Net (2024 - 2026)
Design Therapeutics (DSGN) posted quarterly Interest Income - Net of -$1.2 million for Q2 2026, down 377.47% year-over-year from $435361.8 in Q2 2025, and up 6.07% on a QoQ basis from -$1.3 million in Q1 2026.
Design Therapeutics (DSGN) Interest Income - Net (2024 - 2026) Analysis & Trends
Design Therapeutics has reported Interest Income - Net for 3 years, with the latest figure at -$1.2 million in Q2 2026.
- Interest Income - Net for Q2 2026 came in at -$1.2 million, down 377.47% year-over-year; the trailing twelve-month figure through Jun 2026 was -$2.5 million (down 296.96% YoY), and the FY2025 annual result was -$53.7 billion, down 173.54% from the prior year.
- Interest Income - Net advanced to -$1.2 million in Q2 2026, from -$1.3 million in the prior quarter.
- Over five years, Interest Income - Net peaked at $1.1 million in Q1 2024 and troughed at -$1.3 million in Q1 2026.
- A 3-year average of $93300.0 and a median of $104000.0 in 2025 frame the typical range for Interest Income - Net.
- The widest annual swing landed in 2025, when Interest Income - Net sank 85.29%; it then sank 893.83% in 2026.
- A 3-year view of Interest Income - Net shows it stood at $406000.0 in 2024, then sank by 103.45% to -$14000.0 in 2025, then slumped by 8528.57% to -$1.2 million in 2026.
- Per Business Quant data, the three most recent Interest Income - Net figures were -$1.2 million in Q2 2026, -$1.3 million in Q1 2026, and -$14000.0 in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Income - Net (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Design Therapeutics | 928.06 Mn | 720.67 Mn | - | -1.21 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -1.21 Mn |
| Mar 31, 2026 | -1.29 Mn |
| Dec 31, 2025 | -14,000.00 |
| Sep 30, 2025 | 46,000.00 |
| Jun 30, 2025 | -253,000.00 |
| Mar 31, 2025 | 162,000.00 |
| Dec 31, 2024 | 406,000.00 |
| Sep 30, 2024 | 935,000.00 |
| Jun 30, 2024 | 1.04 Mn |
| Mar 31, 2024 | 1.10 Mn |